reason report
skyrizi launch signal start abbvi immunolog portfolio
bottom line yesterday market close fda approv
abbvi skyrizi risankizumab antibodi psoriasi
approv wide anticip base stellar phase result
clear skin lesion pasi patient
week see analysi clinic data risankizumab
might realli best class psoriasi increas
one year main controversi
much quickli compani transit psoriasi patient
skyrizi humira expect face biosimilar competit
us start alreadi erod ex-u compani
plan launch skyrizi us earli may look
upcom confer call thursday hear commentari
commerci strategi price skyrizi
skyrizi second pure approv follow jnj
op tremfya advantag skyrizi dose
compar tremfya schedul skyrizi approv also follow
three biolog use heavili psoriasi indic includ
stelara cosentyx taltz includ
otezla oral drug psoriasi drug report global
sale grew prior year includ
sale anti-tnf psoriasi decreas patient
move new efficaci therapi product also
achiev second year launch like
also achiev skyrizi overal biolog still use
moder sever psoriasi popul per
abbvi skyrizi benefit best-in-categori efficaci
market share gain continu rapid market expans
surpris skyrizi label skyrizi dose subcutan sc
inject two load dose week
week sc dose thereaft label warn increas risk
infect includ tuberculosi headach inject site reaction
common biolog approv psoriasi
rate low seriou hypersensit report
case malign
undisclos royalti mileston due partner
boehring ingelheim obtain risankizumab boehring
paid up-front right molecul
boehring also receiv undisclos royalti sale product
abil receiv aggreg amount approxim
billion develop regulatori mileston portion
like paid alreadi
underway beyond psoriasi skyrizi phase crohn diseas
ulcer coliti trial activ recruit induct
mainten studi design studi gener
week induct endpoint mainten endpoint
respond expect induct data could avail
pleas refer page import disclosur price chart analyst certif
full mainten data report skyrizi also like becom
import drug psoriat arthriti phase trial on-going
addit slow growth taltz cosentyx erod
residu revenu tnf longer term expect potent biolog
tremfya skyrizi threaten robust growth trajectori
svb leerink estim consensu target
includ probabl adjust skyrizi current
estim adjust sale skyrizi
peak estim recent consensu
releas long-term
revenu target includ risankizumab sale
psoriasi
inflammatori bowel diseas learn price
commerci strategi skyrizi compani earn call week
expect updat model revenu forecast product
geoffrey porg mbb certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori abbvi inc
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach simpl price earn multipl compar larg
biopharmaceut compani price sale multipl larg cap peer compani stock discount cash
flow dcf appli peer ep revenu multipl use averag larg cap larg molecul therapeut
compani mid-term growth tail risk celg averag consensu ep
multipl appli current ep estim give valu use
revenu multipl similar compani consensu sale appli revenu
estim give valu lastli dcf valuat given wacc termin
cash flow growth rate begin humira biosimilar entri give present valu averag
three method current price target upon complet analysi quarterli result
revisit price target present remain unchang
risk valuat
risk view outlook valuat includ major chang price outlook reimburs
coverag label competit posit humira compani main product risk includ commerci
develop disappoint compani follow-on program inflammatori diseas imbruvica
venclexta expand hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow dividend
reduct forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ stronger-than-expect
price volum share humira emerg tangibl demand underappreci element
compani early-to-mid stage pipelin asset potenti label expans opportun late stage opportun
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target price target appli
price-to-earnings multipl ep estim share current trade ep estim
large-cap med-tech group rang price target
assum see multipl expans line broader comp group compani manag
top-lin headwind continu drive oper leverag -- posit sustain
ep out-performance view total return capabl attract increasingli volatil stock market
environ like attract fund riskier area
risk valuat
risk includ failur success integr auri potenti futur acquisit failur resolv
outstand consum consent decre success re-launch product product recal failur
advanc late-stag pipelin success launch new product protract recoveri procedur volum
trend lack real macroeconom recoveri
rate price target histori celgen corpor celg
leerink place market perform rate celg februari
creat bluematrix
price target celgen celg base simpl averag three approach believ
reason basi valu stock today approach simpl price earn multipl compar
high growth larg cap medic product drug devic compani present valu base price sale multipl
peer coverag discount cash flow dcf analysi use averag peer mature/end patent life
larg cap biopharma compani multipl consensu ep appli ep
estim celgen support one-year price target use exclus matur biopharma
sni price sale multipl revenu appli revenu estim give fair valu
share lastli dcf use estim compani current wacc appli period cash flow
assum annual declin cash flow termin valu adjust cash
debt give present valu per share averag three approach current price target
upon complet analysi quarterli result revisit price target present remain
risk valuat
risk view outlook valuat celgen includ major chang price reimburs
coverag revlimid compani main product today risk includ commerci develop
disappoint compani diversifi program otezla ozanimod lastli challeng
compani revlimid patent posit would view neg investor would larg dilut acquisit
research invest could undermin compani oper profit return
invest capit opportun greater upsid current forecast includ success develop
commerci program compani celmod platform addit cellular therapi product
stem juno acquisit announc propos acquisit bristol-my squibb
risk deal close close time manner
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
